Siemens and BioNTech have partnered to establish a paperless, commercial-scale good manufacturing practice (GMP) production facility for personalised cancer vaccines.

The strategic collaboration will focus on construction of a fully automated and digitalised production site to provide capacity for BioNTech’s IVAC individualised vaccines to serve worldwide markets.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BioNTech’s IVAC Mutanome Immunotherapy approach, currently in a Phase I/IIa clinical trial for treatment of malignant melanoma, targets the unique mutation signature of an individual patient’s tumour.

"We will pave the way for a digital plant with an efficient and completely paperless production."

Subsidiaries BioNTech RNA Pharmaceuticals and EUFETS will work with Siemens on construction of the site and to establish and integrate all required process and production steps for larger scale manufacturing of the vaccine.

Siemens Business Unit Process Automation CEO Eckard Eberle said: "The development and manufacturing of personalised medicine is connected with massive amounts of data.

See Also:

"Solutions such as our manufacturing operations management (MOM) software are able to handle the complexity of this innovative new process technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Together with BioNTech’s competence in individualised medicine, we will pave the way for a digital plant with an efficient and completely paperless production."

Siemens’ paperless manufacturing solution not only enhances both efficiency and product quality, but also reduces costs.

The solution serves as a central access point for all process and quality relevant data, connects advanced scheduling with the manufacturing execution and the laboratory management system.

This paperless manufacturing also enables complete electronic recording and documentation of quality-related production data, while accelerating the design, execution, review and release of pharmaceutical production processes and electronic batch records (EBRs).